Loading...
Case Summary
A 63-year-old female with vitiligo and underlying autoimmune disorder on Ruxolitinib experienced visible repigmentation in previously depigmented patches along with increased collagen and elastin production.
Presenting Complaint
Patient presented with vitiligo characterized by depigmented patches due to loss of melanocytes. Despite treatment with immunosuppressives including Ruxolitinib for her autoimmune disorder, she had not experienced significant improvement.
Clinical Course
The regenerative cell therapy targeted underlying factors contributing to depigmentation and aimed to stimulate melanocyte regeneration over six months of treatment.
Clinical Outcomes
Phenotypic changes in epidermal melanocytes
Repigmentation in previously depigmented patches
Increased collagen and elastin production
Tightening of skin at neck and jaw lines
Long-term efficacy confirmed at follow-up
Patient Information
Age / Gender
63 years / Female
Ethnicity
White
Treatment Protocol
Sessions
6 treatments
Duration
6 months
Total Units
36 units (6/session)
Administration Routes
Intravenous (IV)Subcutaneous (SQ)Topical micro-channel
Download Full Case Study
Access the complete clinical documentation with detailed findings and supporting data.
Disclaimer: This case study is provided for educational and informational purposes only. Individual results may vary. This material is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare provider before beginning any treatment protocol.